Skip to main content
Top
Published in: European Archives of Oto-Rhino-Laryngology 10/2010

01-10-2010 | Editorial

Predictive value of fluorodeoxyglucose uptake in head and neck cancer: importance of standardization

Editorial on EAORL-D-10-00277

Authors: Remco de Bree, Otto S. Hoekstra

Published in: European Archives of Oto-Rhino-Laryngology | Issue 10/2010

Login to get access

Excerpt

In the past the majority of patients with advanced stage head and neck squamous cell carcinoma (HNSCC) were treated with a combination of surgery and radiotherapy, often at the expense of functional and cosmetic morbidity, and thus reduced quality of life. Nowadays, in an attempt to decrease the morbidity, non-surgical treatments for advanced HNSCC are increasingly applied with considerable complete remission rates. It appeared that new radiation schemes (accelerated or hyperfractionated) and combinations of chemotherapy and radiotherapy all increase remission rates. When starting an organ sparing non-surgical therapy for functionally inoperable HNSCC (i.e. too high morbidity of surgical treatment expected), salvage surgery is held in reserve for residual or recurrent disease. However, salvage surgery with curative intent is only possible in about half of such patients. Moreover, the complication rate of salvage surgery after chemoradiation is high, with wound healing problems as a well-known complication. Since non-surgical treatment itself is also associated with acute and long-term side effects, leading to compromised quality of life, patients undergoing primary non-surgical treatment (radiotherapy with or without chemotherapy) followed by salvage surgery are exposed to cumulative morbidity of all treatment modalities. Another important disadvantage of surgery for residual or recurrent tumour after radiotherapy is the fact that although it may be indicated postoperative radiotherapy is mostly no longer possible, limiting the oncological outcome of this treatment. …
Literature
1.
go back to reference Weber WA, Ziegler SI, Thödtmann R et al (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771–1777PubMed Weber WA, Ziegler SI, Thödtmann R et al (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771–1777PubMed
2.
go back to reference Brun E, Kjellen E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24:127–135CrossRefPubMed Brun E, Kjellen E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24:127–135CrossRefPubMed
3.
go back to reference Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines foor tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200CrossRefPubMed Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines foor tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200CrossRefPubMed
4.
go back to reference Farrag A, Ceulemans G, Voordeckers M et al (2010) Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 31:495–501PubMed Farrag A, Ceulemans G, Voordeckers M et al (2010) Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 31:495–501PubMed
5.
go back to reference Minn H, Lapela M, Klemi PJ et al (1997) Prediction of survival with Fluorine-18-Fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911PubMed Minn H, Lapela M, Klemi PJ et al (1997) Prediction of survival with Fluorine-18-Fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911PubMed
6.
go back to reference Kim SY, Roh JL, Kim RA et al (2007) Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48:752–757CrossRefPubMed Kim SY, Roh JL, Kim RA et al (2007) Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48:752–757CrossRefPubMed
7.
go back to reference Halfpenny W, Hain SF, Biassoni L et al (2002) FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 86:512–516CrossRefPubMed Halfpenny W, Hain SF, Biassoni L et al (2002) FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 86:512–516CrossRefPubMed
8.
go back to reference Allal AS, Dulguerov P, Allaoua M et al (2002) Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20:1398–1404CrossRefPubMed Allal AS, Dulguerov P, Allaoua M et al (2002) Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20:1398–1404CrossRefPubMed
9.
go back to reference Torizuka T, Tanizaki Y, Kanno T et al (2009) Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 192:W156–W160CrossRefPubMed Torizuka T, Tanizaki Y, Kanno T et al (2009) Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 192:W156–W160CrossRefPubMed
10.
go back to reference Machtay M, Natwa M, Andrel J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31:195–201CrossRefPubMed Machtay M, Natwa M, Andrel J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31:195–201CrossRefPubMed
11.
go back to reference Inokuchi H, Kodaira T, Tachibana H et al (2010) Clinical usefulness of [(18)F] Fluoro-2-Deoxy-d-Glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys 2010Apr 29. [Epub ahead of print] Inokuchi H, Kodaira T, Tachibana H et al (2010) Clinical usefulness of [(18)F] Fluoro-2-Deoxy-d-Glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys 2010Apr 29. [Epub ahead of print]
12.
go back to reference Haerle SK, Huber GF, Hany TF et al (2010) Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck? Eur Arch Otorhinolaryngol. doi:10.1007/s00405-010-1348-2 Haerle SK, Huber GF, Hany TF et al (2010) Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck? Eur Arch Otorhinolaryngol. doi:10.​1007/​s00405-010-1348-2
13.
go back to reference Price P, Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31A:1924–1927CrossRefPubMed Price P, Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31A:1924–1927CrossRefPubMed
14.
go back to reference Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival and recurrence in adenocarcinoma of the esophagogastric junction. J Clin Oncol 24:4692–4698CrossRefPubMed Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival and recurrence in adenocarcinoma of the esophagogastric junction. J Clin Oncol 24:4692–4698CrossRefPubMed
15.
go back to reference Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging; results of a prospective trial. J Clin Oncol 24:4604–4610CrossRef Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging; results of a prospective trial. J Clin Oncol 24:4604–4610CrossRef
16.
go back to reference Dalsaso TA, Lowe VJ, Dunphy FR et al (2000) FDG-PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging 3:1–5CrossRefPubMed Dalsaso TA, Lowe VJ, Dunphy FR et al (2000) FDG-PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging 3:1–5CrossRefPubMed
17.
go back to reference Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11s–20sCrossRefPubMed Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11s–20sCrossRefPubMed
Metadata
Title
Predictive value of fluorodeoxyglucose uptake in head and neck cancer: importance of standardization
Editorial on EAORL-D-10-00277
Authors
Remco de Bree
Otto S. Hoekstra
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
European Archives of Oto-Rhino-Laryngology / Issue 10/2010
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-010-1350-8

Other articles of this Issue 10/2010

European Archives of Oto-Rhino-Laryngology 10/2010 Go to the issue